Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Search
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
Data science, agile working, UX design: our evolving IT careers
Meet our IT colleagues working in the fields of user experience, data science and agile development
recipe_tomato_rigatoni.pdf
Aftopor®/Aftovaxpur®/Aftovax®
FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
Combating complex diseases with data
How does big data create disrupting insights for our company? Read about potential use cases and promoting a data mindset
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Helping smallholder farmers after Covid-19
In Ghana, we are helping smallholder farmers overcome hardship caused by the pandemic.
FDA approves Jardiance treatment chronic kidney disease
U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease
10 things you should know about rabies
10 things you should know about rabies
Boehringer unveils first global sustainability publication
Boehringer Ingelheim unveils its first global sustainability publication ‘Imagine’
tomato_and_carrot_soup.pdf
TOviTO_Wheel_Interactive_PDF_05122018_2.pdf
tovito_info_0.pdf
Boehringer Ingelheim Office Hours Video 2023
Boehringer Ingelheim’s Office Hours program provides mentoring and access to expertise to help early-stage companies advance their science.
LastMile – improving through digital
LastMile initiative is an integrated, solutions-driven program seeking to make animal medical resources available in hard-to-reach areas in Africa.
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Metabolic Diseases
Metabolic Diseases
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
1885-1948: Innovative beginnings
The Boehringer Ingelheim history from its start in 1885 to 1948, with milestones and important products
1948-1990: Going global
The Boehringer Ingelheim history from 1948-1990, with milestones